The point of starting Oncotarget was so that Mikhail Blagosklonny would have a place where he could research different things. He tried hard to make sure that he was doing everything right and that he would be able to show people different opportunities for treatment. It was something that was a huge part of the review publication where peers could do research on different subjects. It was also something that Mikhail Blagosklonny was confident in and something that he tried hard to make better for all of the people who he was working with. Since Mikhail Blagosklonny started Oncotarget, he has been able to learn different things and has been able to make things better for all of the other peers that are a part of the publication with the different options that they have available to them and in the different areas that they are experts on cancer treatment.
The expert advice that Mikhail Blagosklonny has been giving to people is something that makes Oncotarget so valuable. Without it, doctors wouldn’t be able to connect with Oncotraget who are not in their special fields. They would worry about what they could be doing for their patients and they would probably be concerned about the issues that were going on in their fields. It was something that made it hard for people to realize and something that was different from anything else that other companies had offered in the past.
Mikhail Blagosklonny knew that Oncotarget could be successful for other people.Since Oncotarget has grown and more specialists have joined the publication, Mikhail Blagosklonny has seen a lot of changes. He has been able to keep track of the different things that Oncotarget does and that has helped him to make a difference in the world that he is in. Mikhail Blagosklonny is confident with the skills that he has and he has tried hard to make Oncotarget better. All of the people who work with Oncotarget also work to make sure that others are going to be able to benefit from it so that they can try different things in the practices that they have.